- Home
- SGA vs ACET Comparison
SGA vs ACET Comparison
Compare SGA & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGA
- ACET
- Stock Information
- Founded
- SGA 1986
- ACET 1947
- Country
- SGA United States
- ACET United States
- Employees
- SGA N/A
- ACET N/A
- Industry
- SGA Broadcasting
- ACET Biotechnology: Pharmaceutical Preparations
- Sector
- SGA Consumer Discretionary
- ACET Health Care
- Exchange
- SGA Nasdaq
- ACET Nasdaq
- Market Cap
- SGA 79.0M
- ACET 83.2M
- IPO Year
- SGA 1992
- ACET N/A
- Fundamental
- Price
- SGA $12.03
- ACET $0.98
- Analyst Decision
- SGA
- ACET Buy
- Analyst Count
- SGA 0
- ACET 5
- Target Price
- SGA N/A
- ACET $5.67
- AVG Volume (30 Days)
- SGA 12.1K
- ACET 1.6M
- Earning Date
- SGA 03-06-2025
- ACET 03-18-2025
- Dividend Yield
- SGA 8.31%
- ACET N/A
- EPS Growth
- SGA N/A
- ACET N/A
- EPS
- SGA 0.75
- ACET N/A
- Revenue
- SGA $110,669,000.00
- ACET N/A
- Revenue This Year
- SGA N/A
- ACET N/A
- Revenue Next Year
- SGA $2.64
- ACET N/A
- P/E Ratio
- SGA $16.03
- ACET N/A
- Revenue Growth
- SGA N/A
- ACET N/A
- 52 Week Low
- SGA $10.75
- ACET $0.81
- 52 Week High
- SGA $24.67
- ACET $2.61
- Technical
- Relative Strength Index (RSI)
- SGA 42.96
- ACET 57.01
- Support Level
- SGA $12.23
- ACET $0.84
- Resistance Level
- SGA $12.94
- ACET $1.04
- Average True Range (ATR)
- SGA 0.31
- ACET 0.08
- MACD
- SGA -0.08
- ACET 0.01
- Stochastic Oscillator
- SGA 1.98
- ACET 68.65
About SGA Saga Communications Inc. (FL)
Saga Communications Inc is a broadcast company engaged in acquiring, developing, and operating broadcast properties. The company's objective is to operate top billing radio stations in mid-sized markets and It derives a majority of its revenue from the sale of advertising for broadcast on its stations.
About ACET Adicet Bio Inc.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its lead product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its lead preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.